Results 71 to 80 of about 6,775 (167)
European Journal of Haematology, Volume 117, Issue 2, Page 375-383, August 2026.ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta +13 more
wiley +1 more source
AboutOpen, 2019 Introduction: Multicriteria Decision Analysis (MCDA) provides a framework that enhances transparency and repeatability of decisions taken on a multicriteria basis. Objective: This analysis aims at assessing obinutuzumab compared to rituximab used as a
Claudio Jommi, Roberto Ravasio
doaj +1 more source
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management
European Journal of Haematology, Volume 117, Issue 2, Page 305-319, August 2026.ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino +13 more
wiley +1 more source
A Review and Future Perspective on Renal Outcome Definitions in Lupus Nephritis
ACR Open Rheumatology, Volume 8, Issue 7, July 2026.Lupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus, yet the lack of standardized definitions for renal outcomes hinders effective diagnosis, prognosis, treatment personalization, comparisons across trials, and interpretable trial endpoints.
Ioannis Parodis +4 more
wiley +1 more source
Frontiers in PharmacologyBackgroundObinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL).
Chao Wang +11 more
doaj +1 more source
Advanced Science, Volume 13, Issue 42, 28 July 2026.ABSTRACT Follicular lymphoma (FL) remains an incurable B‐cell malignancy with high relapse rates, and conventional therapies are often limited by significant toxicity, highlighting the need for novel treatments. We identified that FL exhibits markedly low expression of NAD(P)H: quinone oxidoreductase 1 (NQO1), a key enzyme required for activating ...
Jinxing Zhang +10 more
wiley +1 more source
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain [PDF]
, 2016 Luis Felipe Casado,1 Amparo Burgos,2 Eva González-Haba,3 Javier Loscertales,4 Tania Krivasi,5 Javier Orofino,6 Carlos Rubio-Terres,7 Darío Rubio-Rodríguez7 1Hematology Department, Hospital Virgen de la Salud, Toledo, Spain; 2Pharmacy
Casado LF +7 more
core
Obinutuzumab jako nowa szansa terapeutyczna dla chorych na przewlekłą białaczkę limfocytową [PDF]
, 2015 Obinutuzumab (also known as GA101) is a humanized, glycoengineered type II monoclonal antibody targeted against CD20. Studies in animal models suggest that obinutuzumab shows superior efficacy, as compared with rituximab, by inducing direct cell death ...
Karczmarczyk, Agnieszka +1 more
core +2 more sources
Future Science OA, 2019 Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients.
Ricardo García-Muñoz +15 more
doaj +1 more source